BioCentury
ARTICLE | Company News

Sigma-Tau, Baxter deal

May 18, 2015 7:00 AM UTC

Baxter will purchase a portfolio of leukemia products from Sigma-Tau’s Sigma-Tau Finanziaria S.p.A. unit for $900 million. The portfolio includes Oncaspar pegasparagase, which is marketed to treat ac...